| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 622 | 572 | 573 | 547 | 579 | 503 | 526 | 529 | 539 |
| Expenses | 368 | 393 | 377 | 370 | 400 | 367 | 404 | 397 | 364 |
| EBITDA | 254 | 179 | 195 | 177 | 179 | 137 | 122 | 132 | 175 |
| Operating Profit % | 29 % | 24 % | 23 % | 21 % | 22 % | 21 % | 23 % | 23 % | 32 % |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 244 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 |
| Tax | 54 | 46 | 34 | 30 | 33 | 24 | 30 | 31 | 46 |
| Net Profit | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 |
| EPS in ₹ | 82.78 | 53.37 | 65.95 | 59.79 | 59.31 | 44.81 | 35.69 | 39.64 | 51.89 |
Sanofi
Sanofi
4,113.90
+44.90
(1.10%)
Market Cap
₹9,474.57 Cr
PE Ratio
23.65
Volume
11,485.00
Day High - Low
₹4,131.90 - ₹4,086.90
52W High-Low
₹6,717.00 - ₹4,058.00
Key Fundamentals
Market Cap
9,474.57 Cr
EPS
179.46
PB Ratio
10.89
Book Value
373.70
EBITDA
507.30
Dividend Yield
2.87 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
36.45
Debt to Equity
0.02
Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Sanofi India receives GST order from Ahmedabad authorities demanding ₹35.63 lakh for FY2018-19, comprising tax, interest, and penalty. Company plans to appeal the decision.
Sanofi India Seeks Shareholder Approval for Deepak Arora's Appointment as Managing Director
Nov 17, 2025
Nov 17, 2025Sanofi India has issued a postal ballot notice seeking member approval for appointing Deepak Arora as Director and Managing Director for a 3-year term from October 27, 2025 to October 26, 2028. The appointment requires Central Government approval as Arora has not been residing in India for the required 12 months prior to appointment, with e-voting scheduled from November 18 to December 17, 2025.
Sanofi Consumer Healthcare India Reports Strong Q2 Growth with 40% Revenue JumpNov 12, 2025
Sanofi Consumer Healthcare India delivered robust Q2 performance with net profit rising to 629 million rupees from 450 million rupees in the same period last year. Revenue grew significantly to 2.3 billion rupees compared to 1.6 billion rupees year-over-year. EBITDA increased to 850 million rupees from 631 million rupees, though EBITDA margin declined to 36.34% from 39.46% in the previous year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,769.80 | #1 4,24,634.30 | 39.93 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 49.55 | |
6,511.50 | 1,72,859.87 | 69.20 | 9,712.00 | 18.67 | 2,191 | 35.10 | 56.33 | |
3,816.00 | 1,29,150.78 | 60.10 | 11,539.40 | 6.99 | 1,911 | 30.46 | 61.47 | |
1,512.90 | 1,22,205.11 | 22.55 | 28,409.50 | 7.12 | 5,291 | 3.71 | 49.47 | |
1,283.40 | 1,07,114.33 | 18.60 | 33,741.20 | 16.73 | 5,725 | -0.38 | 60.05 | |
2,126.30 | 97,119.71 | 22.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 65.28 | |
918.20 | 92,392.40 | #1 18.40 | 23,511.00 | 18.55 | 4,615 | 34.60 | 40.07 | |
2,186.30 | 90,241.39 | 50.59 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 45.53 | |
1,224.50 | 71,119.16 | 20.79 | 32,345.60 | 9.43 | 3,484 | 3.81 | 59.88 | |
5,624.00 | 67,243.36 | 27.59 | 13,458.30 | 3.70 | 2,216 | 10.98 | 49.80 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-1.34 %
Net Income Growth
-13.96 %
Cash Flow Change
100.30 %
ROE
1.50 %
ROCE
-2.71 %
EBITDA Margin (Avg.)
-6.33 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 |
| Total Assets | 1,715 | 1,612 |
| Fixed Assets | 315 | 313 |
| Current Assets | 1,248 | 1,127 |
| Capital Work in Progress | 16 | 18 |
| Investments | 0 | 0 |
| Other Assets | 1,384 | 1,281 |
| Total Liabilities | 1,715 | 1,612 |
| Current Liabilities | 651 | 719 |
| Non Current Liabilities | 48 | 32 |
| Total Equity | 1,015 | 861 |
| Reserve & Surplus | 992 | 838 |
| Share Capital | 23 | 23 |
Cash Flow
| Cash Flow | 2023 | 2024 |
| Net Cash Flow | -610 | -111 |
| Investing Activities | 38 | -180 |
| Operating Activities | 230 | 462 |
| Financing Activities | -878 | -392 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 6.80 % | 0.00 % | 6.11 % | 5.81 % | 5.78 % | 5.63 % | 5.57 % | 5.61 % | 5.57 % |
| DIIs | 17.16 % | 17.39 % | 17.65 % | 19.03 % | 18.65 % | 18.60 % | 18.27 % | 19.21 % | 19.47 % | 19.66 % | 21.69 % | 22.47 % | 23.08 % | 22.79 % | 22.82 % | 22.93 % | 23.02 % | 23.06 % | 22.29 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.97 % | 7.09 % | 7.21 % | 7.01 % | 7.65 % | 7.92 % | 8.81 % | 9.13 % | 9.29 % | 8.89 % | 8.60 % | 8.09 % | 7.97 % | 8.31 % | 8.21 % | 8.33 % | 8.38 % | 8.33 % | 9.08 % |
| Others | 15.48 % | 15.12 % | 14.74 % | 13.56 % | 13.30 % | 13.09 % | 12.53 % | 11.26 % | 10.85 % | 11.05 % | 2.51 % | 9.04 % | 2.44 % | 2.69 % | 2.79 % | 2.70 % | 2.63 % | 2.61 % | 2.67 % |
| No of Share Holders | 0 | 48,465 | 53,567 | 51,646 | 50,916 | 59,276 | 64,542 | 73,734 | 76,694 | 71,513 | 68,598 | 62,870 | 61,849 | 67,662 | 66,211 | 66,401 | 68,196 | 66,790 | 71,395 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 71 | 84 | 349 | 365 | 490 | 570 | 167 | 117 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.37 | 1.44 | 5.58 | 4.63 | 6.53 | 10.15 | 2.06 | 2.04 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Apr 2021 |  Dividend | ₹ 125.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 21 Apr 2021 | Dividend | ₹ 240.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 16 Apr 2022 | Dividend | ₹ 181.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 16 Apr 2022 | Dividend | ₹ 309.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 26 Apr 2022 |  Annual General Meeting | NA | 26 Apr 2022 | 7,136.45 | 6,979.40 |
| 08 Aug 2022 | Dividend | ₹ 193.00 /share | 05 Aug 2022 | 6,749.00 | 6,542.60 |
| 29 Apr 2023 | Dividend | ₹ 194.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 29 Apr 2023 | Dividend | ₹ 183.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 11 May 2023 | Annual General Meeting | NA | 11 May 2023 | 5,399.30 | 5,700.45 |
| 18 Dec 2023 |  Extraordinary General Meeting | NA | 18 Dec 2023 | 7,804.20 | 8,054.90 |
| 07 Mar 2024 | Dividend | ₹ 50.00 /share | 07 Mar 2024 | 9,208.85 | 8,529.75 |
| 03 May 2024 | Dividend | ₹ 117.00 /share | 03 May 2024 | 9,208.85 | 8,679.45 |
| 14 May 2024 | Annual General Meeting | NA | 14 May 2024 | 9,208.85 | 7,995.05 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 7,024.25 | 6,583.05 |
| 27 Feb 2025 | Quarterly Result Announcement | NA | 27 Feb 2025 | 5,358.40 | 5,059.65 |
| 25 Apr 2025 | Dividend | ₹ 117.00 /share | 25 Apr 2025 | 5,059.65 | 6,570.50 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 5,754.70 | 5,928.60 |
| 15 May 2025 | Annual General Meeting | NA | 15 May 2025 | 5,568.15 | 6,042.35 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 5,955.65 | 5,881.95 |
| 29 Oct 2025 | Quarterly Result Announcement | NA | 29 Oct 2025 | 4,772.95 | 4,746.30 |
| 07 Nov 2025 | Dividend | ₹ 75.00 /share | 07 Nov 2025 | 4,746.30 | 4,744.85 |
Announcements
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 20159 hours ago
9 hours agoDisclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20152 days ago
2 days agoShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot4 days ago
4 days ago Shareholder Meeting / Postal Ballot-Scrutinizer"s Report4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationNov 18, 2025
Nov 18, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 04, 2025
Nov 04, 2025Intimation Of Record DateOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationOct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesOct 29, 2025
Oct 29, 2025Financial Results For The Quarter And Nine Months Ended 30Th September 2025Oct 29, 2025
Oct 29, 2025Board Meeting Outcome for Financials Results For The Quarter Ended 30Th September 2025 And Recommendation Of Interim DividendOct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-CessationOct 27, 2025
Oct 27, 2025Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 27Th October 2025Oct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateOct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 23, 2025
Oct 23, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Statements For The Quarter And Nine-Months Ended 30Th September 2025 And Declaration Of Interim Dividend For The Year 2025 If Any.Oct 23, 2025
Oct 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 18, 2025
Oct 18, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 16, 2025
Oct 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Appointment of Company Secretary and Compliance OfficerSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerSep 25, 2025
Sep 25, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-RetirementJul 31, 2025
Jul 31, 2025Financial Results For The Quarter And Half-Year Ended 30Th June 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Financial Results For The Quarter And Half-Year Ended 30Th June 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements For The Quarter And Half-Year Ended 30Th June 2025Jul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held On 16Th July 2025Jul 16, 2025
Jul 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.May 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 24, 2025
May 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 22, 2025
May 22, 2025Mutual Fund Holdings
SBI Mid Cap Direct Plan-Growth 
Baroda BNP Paribas Midcap Fund Direct-Growth 
Aditya Birla Sun Life Mid Cap Direct Fund-Growth 
Motilal Oswal Quant Fund Direct-Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
HDFC BSE 500 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
LIC MF Small Cap Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 20.50
ATR(14)
Less Volatile 72.19
STOCH(9,6)
Oversold 4.32
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -14.14
ADX(14)
Strong Trend 38.33
UO(9)
Bullish 26.00
ROC(12)
Downtrend And Accelerating -7.51
WillR(14)
Oversold -97.08
About Sanofi
Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Chairperson NameAditya Narayan
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
